| Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset C Harly, Y Guillaume, S Nedellec, CM Peigné, H Mönkkönen, ... Blood, The Journal of the American Society of Hematology 120 (11), 2269-2279, 2012 | 574 | 2012 |
| Expansion of primitive human hematopoietic stem cells by culture in a zwitterionic hydrogel T Bai, J Li, A Sinclair, S Imren, F Merriam, F Sun, MB O’Kelly, C Nourigat, ... Nature medicine 25 (10), 1566-1575, 2019 | 206 | 2019 |
| Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vγ9Vδ2 T cells J Li, MJ Herold, B Kimmel, I Muller, B Rincon-Orozco, V Kunzmann, ... The Journal of Immunology 182 (12), 8118-8124, 2009 | 133 | 2009 |
| Vγ9Vδ2 TCR‐activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6 F Riaño, MM Karunakaran, L Starick, J Li, CJ Scholz, V Kunzmann, ... European journal of immunology 44 (9), 2571-2576, 2014 | 92 | 2014 |
| Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial P Lu, Y Liu, J Yang, X Zhang, X Yang, H Wang, L Wang, Q Wang, D Jin, ... Blood, The Journal of the American Society of Hematology 140 (4), 321-334, 2022 | 89 | 2022 |
| Butyrophilin 3A (BTN3A, CD277)‐specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activation L Starick, F Riano, MM Karunakaran, V Kunzmann, J Li, M Kreiss, ... European journal of immunology 47 (6), 982-992, 2017 | 57 | 2017 |
| First-in-human trial of EphA2-redirected CAR T-cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose Q Lin, T Ba, J Ho, D Chen, Y Cheng, L Wang, G Xu, L Xu, Y Zhou, Y Wei, ... Frontiers in oncology 11, 694941, 2021 | 51 | 2021 |
| Evidence of long‐lasting anti‐CD19 activity of engrafted CD19 chimeric antigen receptor–modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia F Ma, JY Ho, H Du, F Xuan, X Wu, Q Wang, L Wang, Y Liu, M Ba, Y Wang, ... Hematological oncology 37 (5), 601-608, 2019 | 41 | 2019 |
| Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia X Zhang, J Yang, J Li, W Li, D Song, X Lu, F Wu, J Li, D Chen, X Li, Z Xu, ... Cancer Immunology, Immunotherapy 71 (3), 689-703, 2022 | 31 | 2022 |
| Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo JY Ho, L Wang, Y Liu, M Ba, J Yang, X Zhang, D Chen, P Lu, J Li Molecular Therapy-Methods & Clinical Development 21, 237-246, 2021 | 26 | 2021 |
| A feasibility and safety study of CD19 and CD22 chimeric antigen receptors-modified T cell cocktail for therapy of B cell acute lymphoblastic leukemia J Yang, J Li, X Zhang, LV Fanyong, X Guo, Q Wang, L Wang, D Chen, ... Blood 132, 277, 2018 | 26 | 2018 |
| Distinct pattern of human Vdelta1 gammadelta T cells recognizing MICA J Li, L Cui, W He Cell Mol Immunol 2 (4), 253-8, 2005 | 23 | 2005 |
| Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report D Wang, R Shi, Q Wang, J Li OncoTargets and therapy, 6327-6332, 2018 | 13 | 2018 |
| CD1 分子的研究进展 崔永春， 李建强 国际免疫学杂志 29 (3), 129-132, 2006 | 13 | 2006 |
| High effectiveness and safety of anti-CD7 CAR T-cell therapy in treating relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) J Yang, X Zhang, Y Liu, X Yang, H Wang, L Wang, J Li, P Lu Blood 138, 473, 2021 | 10 | 2021 |
| Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study C Huang, L Wu, R Liu, W Li, Z Li, J Li, L Liu, B Shan Annals of Translational Medicine 8 (17), 2020 | 9 | 2020 |
| Detection and preliminary characterization of CD8+ T lymphocytes specific for Wilms’ tumor antigen in patients with non-Hodgkin lymphoma A Israyelyan, C La Rosa, W Tsai, T Kaltcheva, T Srivastava, L Aquino, J Li, ... Leukemia & lymphoma 54 (11), 2490-2499, 2013 | 9 | 2013 |
| A novel and successful patient or donor-derived CD7-targeted CAR T-cell therapy for relapsed or refractory T-cell lymphoblastic lymphoma (R/R T-LBL) J Yang, X Yang, Y Liu, Q Wang, H Wang, J Li, P Lu Blood 138, 652, 2021 | 8 | 2021 |
| Dual specific CD19/CD22‑targeted chimeric antigen receptor T‑cell therapy for refractory diffuse large B‑cell lymphoma: A case report C Huang, HC Zhang, JY Ho, RX Liu, L Wang, N Kuang, MR Zheng, LH Liu, ... Oncology letters 20 (4), 1-1, 2020 | 7 | 2020 |
| Feasibility, and efficacy of Donor-Derived cd19-Targeted Car t-Cell therapy in Refractory/Relapsed (r/r) b-Cell Acute Lymphoblastic Leukemia (b-all) patients X Zhang, J Yang, W Li, G Zhang, Y Su, Y Shi, D Song, M Zhang, J He, ... Blood 136, 4-6, 2020 | 5 | 2020 |
